Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00619684 · OUTCOME

Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant · Source last updated 2017-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Up to 30 days after completion of study treatment

What was measured

Grade 1-2 adverse events occurring in \>10% of participants. Grade 3 or higher adverse events occurring in one or more participants.

Groups in this outcome

Treatment (Lenalidomide)

Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide)18

Reported measurements

Grade 1-2 constipation
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)28Not reportedNot reportedNot reportedNot reported
Grade 1-2 diarrhea
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)17Not reportedNot reportedNot reportedNot reported
Grade 1-2 fatigue
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)17Not reportedNot reportedNot reportedNot reported
Grade 1-2 myalgia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)17Not reportedNot reportedNot reportedNot reported
Grade 1-2 nausea
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)11Not reportedNot reportedNot reportedNot reported
Grade 1-2 neuropathy
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)11Not reportedNot reportedNot reportedNot reported
Grade 1-2 thrombocytopenia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)11Not reportedNot reportedNot reportedNot reported
Grade 3 pneumonia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)17Not reportedNot reportedNot reportedNot reported
Grade 3 H1N1 influenza
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)11Not reportedNot reportedNot reportedNot reported
Grade 3 fever, hypoxia and neuropathy
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)6Not reportedNot reportedNot reportedNot reported
Grade 3 myalgia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)6Not reportedNot reportedNot reportedNot reported
Grade 3 neuropathy
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)6Not reportedNot reportedNot reportedNot reported
Grade 3 neutropenia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)44Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        28
    title
    Grade 1-2 constipation
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    Grade 1-2 diarrhea
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    Grade 1-2 fatigue
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    Grade 1-2 myalgia
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Grade 1-2 nausea
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Grade 1-2 neuropathy
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Grade 1-2 thrombocytopenia
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    Grade 3 pneumonia
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Grade 3 H1N1 influenza
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Grade 3 fever, hypoxia and neuropathy
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Grade 3 myalgia
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Grade 3 neuropathy
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Grade 1-2 adverse events occurring in \>10% of participants. Grade 3 or higher adverse events occurring in one or more participants.
groups
  1. description
    Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO
    id
    OG000
    title
    Treatment (Lenalidomide)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 30 days after completion of study treatment
title
Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice